Cargando…

Cancer Cell Membrane-Coated Nanoparticles for Cancer Management

Cancer is a global health problem in need of transformative treatment solutions for improved patient outcomes. Many conventional treatments prove ineffective and produce undesirable side effects because they are incapable of targeting only cancer cells within tumors and metastases post administratio...

Descripción completa

Detalles Bibliográficos
Autores principales: Harris, Jenna C., Scully, Mackenzie A., Day, Emily S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6966582/
https://www.ncbi.nlm.nih.gov/pubmed/31766360
http://dx.doi.org/10.3390/cancers11121836
_version_ 1783488769174798336
author Harris, Jenna C.
Scully, Mackenzie A.
Day, Emily S.
author_facet Harris, Jenna C.
Scully, Mackenzie A.
Day, Emily S.
author_sort Harris, Jenna C.
collection PubMed
description Cancer is a global health problem in need of transformative treatment solutions for improved patient outcomes. Many conventional treatments prove ineffective and produce undesirable side effects because they are incapable of targeting only cancer cells within tumors and metastases post administration. There is a desperate need for targeted therapies that can maximize treatment success and minimize toxicity. Nanoparticles (NPs) with tunable physicochemical properties have potential to meet the need for high precision cancer therapies. At the forefront of nanomedicine is biomimetic nanotechnology, which hides NPs from the immune system and provides superior targeting capabilities by cloaking NPs in cell-derived membranes. Cancer cell membranes expressing “markers of self” and “self-recognition molecules” can be removed from cancer cells and wrapped around a variety of NPs, providing homotypic targeting and circumventing the challenge of synthetically replicating natural cell surfaces. Compared to unwrapped NPs, cancer cell membrane-wrapped NPs (CCNPs) provide reduced accumulation in healthy tissues and higher accumulation in tumors and metastases. The unique biointerfacing capabilities of CCNPs enable their use as targeted nanovehicles for enhanced drug delivery, localized phototherapy, intensified imaging, or more potent immunotherapy. This review summarizes the state-of-the-art in CCNP technology and provides insight to the path forward for clinical implementation.
format Online
Article
Text
id pubmed-6966582
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-69665822020-02-04 Cancer Cell Membrane-Coated Nanoparticles for Cancer Management Harris, Jenna C. Scully, Mackenzie A. Day, Emily S. Cancers (Basel) Review Cancer is a global health problem in need of transformative treatment solutions for improved patient outcomes. Many conventional treatments prove ineffective and produce undesirable side effects because they are incapable of targeting only cancer cells within tumors and metastases post administration. There is a desperate need for targeted therapies that can maximize treatment success and minimize toxicity. Nanoparticles (NPs) with tunable physicochemical properties have potential to meet the need for high precision cancer therapies. At the forefront of nanomedicine is biomimetic nanotechnology, which hides NPs from the immune system and provides superior targeting capabilities by cloaking NPs in cell-derived membranes. Cancer cell membranes expressing “markers of self” and “self-recognition molecules” can be removed from cancer cells and wrapped around a variety of NPs, providing homotypic targeting and circumventing the challenge of synthetically replicating natural cell surfaces. Compared to unwrapped NPs, cancer cell membrane-wrapped NPs (CCNPs) provide reduced accumulation in healthy tissues and higher accumulation in tumors and metastases. The unique biointerfacing capabilities of CCNPs enable their use as targeted nanovehicles for enhanced drug delivery, localized phototherapy, intensified imaging, or more potent immunotherapy. This review summarizes the state-of-the-art in CCNP technology and provides insight to the path forward for clinical implementation. MDPI 2019-11-21 /pmc/articles/PMC6966582/ /pubmed/31766360 http://dx.doi.org/10.3390/cancers11121836 Text en © 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Harris, Jenna C.
Scully, Mackenzie A.
Day, Emily S.
Cancer Cell Membrane-Coated Nanoparticles for Cancer Management
title Cancer Cell Membrane-Coated Nanoparticles for Cancer Management
title_full Cancer Cell Membrane-Coated Nanoparticles for Cancer Management
title_fullStr Cancer Cell Membrane-Coated Nanoparticles for Cancer Management
title_full_unstemmed Cancer Cell Membrane-Coated Nanoparticles for Cancer Management
title_short Cancer Cell Membrane-Coated Nanoparticles for Cancer Management
title_sort cancer cell membrane-coated nanoparticles for cancer management
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6966582/
https://www.ncbi.nlm.nih.gov/pubmed/31766360
http://dx.doi.org/10.3390/cancers11121836
work_keys_str_mv AT harrisjennac cancercellmembranecoatednanoparticlesforcancermanagement
AT scullymackenziea cancercellmembranecoatednanoparticlesforcancermanagement
AT dayemilys cancercellmembranecoatednanoparticlesforcancermanagement